Picton Mahoney Asset Management Trims Position in Inogen Inc (NASDAQ:INGN)

Picton Mahoney Asset Management lessened its stake in shares of Inogen Inc (NASDAQ:INGN) by 2.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,800 shares of the medical technology company’s stock after selling 300 shares during the period. Picton Mahoney Asset Management owned 0.06% of Inogen worth $922,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Advisor Group Inc. raised its holdings in shares of Inogen by 71.4% during the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock worth $31,000 after acquiring an additional 192 shares during the period. Hanson McClain Inc. purchased a new position in shares of Inogen during the 1st quarter worth $50,000. TRUE Private Wealth Advisors purchased a new position in shares of Inogen during the 2nd quarter worth $66,000. Victory Capital Management Inc. acquired a new stake in shares of Inogen during the 1st quarter worth about $163,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Inogen during the 2nd quarter worth about $119,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

A number of brokerages recently issued reports on INGN. KeyCorp reissued a “hold” rating on shares of Inogen in a research report on Wednesday, August 7th. Leerink Swann downgraded Inogen from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 8th. Svb Leerink reissued a “market perform” rating and set a $47.00 price objective (down from $78.00) on shares of Inogen in a research report on Thursday, August 8th. Piper Jaffray Companies cut their price objective on Inogen from $140.00 to $80.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Finally, BidaskClub downgraded Inogen from a “sell” rating to a “strong sell” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. Inogen has a consensus rating of “Hold” and a consensus target price of $82.17.

Shares of NASDAQ:INGN traded down $0.11 during midday trading on Friday, reaching $44.60. 464,342 shares of the company’s stock were exchanged, compared to its average volume of 727,474. The firm’s 50 day simple moving average is $55.12 and its two-hundred day simple moving average is $81.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 6.82. The stock has a market cap of $980.67 million, a price-to-earnings ratio of 19.39, a P/E/G ratio of 2.64 and a beta of 1.40. Inogen Inc has a fifty-two week low of $41.19 and a fifty-two week high of $287.79.

Inogen (NASDAQ:INGN) last released its earnings results on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). The firm had revenue of $101.10 million during the quarter, compared to analyst estimates of $106.88 million. Inogen had a net margin of 11.24% and a return on equity of 13.34%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.65 earnings per share. Equities research analysts predict that Inogen Inc will post 1.09 earnings per share for the current fiscal year.

In other news, Director Heath Lukatch bought 2,000 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was bought at an average cost of $43.01 per share, with a total value of $86,020.00. Following the transaction, the director now directly owns 5,481 shares in the company, valued at approximately $235,737.81. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.54% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: What does the Producer Price Index (PPI) tell investors?

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.